|
Radiation Therapy Approaches for People With Prostate Cancer
RECRUITINGPhase 2Sponsored by Memorial Sloan Kettering Cancer Center
Actively Recruiting
PhasePhase 2
SponsorMemorial Sloan Kettering Cancer Center
Started2026-07-31
Est. completion2030-07-31
Eligibility
Healthy vol.Accepted
Locations7 sites
View on ClinicalTrials.gov →
NCT07751159
Summary
The purpose of the study is to explore the best ways of giving radiation therapy to balance cancer control and treatment side effects.
Eligibility
Healthy volunteers accepted
Inclusion Criteria: * Non-metastatic prostate cancer. * Classified as unfavorable intermediate-, high-, or very high-risk prostate cancer according to NCCN risk stratification guidelines. (Note: cT3a or T3b by MRI or PSMA PET allowed) * Considered by the treating radiation oncologist as a suitable candidate for both HDR brachytherapy boost and SBRT Exclusion Criteria: * None
Conditions4
CancerHigh Risk Prostate CancerNon-metastatic Prostate CancerProstate Cancer Patients
Locations7 sites
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey, 07920
Daniel Gorovets, MD212-639-3983
Memorial Sloan Kettering at Monmouth (Limited Protocol Activities)
Middletown, New Jersey, 07748
Daniel Gorovets, MD212-639-3983
Memorial Sloan Kettering at Bergen (Limited Protocol Activities)
Montvale, New Jersey, 07645
Daniel Gorovets, MD212-639-3983
Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)
Daniel Gorovets, MD212-639-3983
Memorial Sloan Kettering at Westchester (Limited Protocol Activities)
Daniel Gorovets, MD212-639-3983
Find trials near these locations
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 2
SponsorMemorial Sloan Kettering Cancer Center
Started2026-07-31
Est. completion2030-07-31
Eligibility
Healthy vol.Accepted
Locations7 sites
View on ClinicalTrials.gov →
NCT07751159